Pharmacological targeting of the NLRP3 LRR domain with isothiazolinones overcomes CRID3-resistant inflammation.
Saved in:
| Title: | Pharmacological targeting of the NLRP3 LRR domain with isothiazolinones overcomes CRID3-resistant inflammation. |
|---|---|
| Authors: | Woo H; Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea., Jang Y; Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea., Kim S; Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea., Kim W; Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea., Zhang F; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China., Mall R; Qatar Computing Research Institute, Hamad Bin Khalifa University, Doha, Qatar., Patel CN; Qatar Computing Research Institute, Hamad Bin Khalifa University, Doha, Qatar.; Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD, USA., Kurera M; Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia., Ngo C; Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia., Jiang SH; Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia., Nicotra A; CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France., Py BF; CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France., Zheng M; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China. min.zheng@szbl.ac.cn., Man SM; Division of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia. siming.man@anu.edu.au., Karki R; Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea. rkarki@snu.ac.kr.; The Institute of Molecular Biology and Genetics (IMBG), Seoul National University, Seoul, Republic of Korea. rkarki@snu.ac.kr. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2026 Jun; Vol. 18 (6), pp. 2124-2151. Date of Electronic Publication: 2026 Apr 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1757-4684 |
|---|---|
| DOI: | 10.1038/s44321-026-00425-5 |
